About: Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome
Creator	Burnouf, Thierry Chen, Zhi-Yu Hsiao, Shun-Hung Renn, Ting-Yi Tseng, Ching-Li Taylor, Andrew
Source	Medline; PMC
abstract	Application of autologous serum eye drops (SEDs) is a recognized means to treat severe dry-eye syndrome (DES). Due to the inconvenience and difficulty of preparing SEDs from some patients, producing SEDs from allogeneic blood donations is gaining popularity. A major safety concern associated with allogeneic blood is virus transmission. We therefore herein evaluated the possibility of applying a solvent/detergent (S/D) treatment to inactivate viruses and studied the impacts of such treatment of SEDs to resolve DES in a rabbit model. Sera prepared from the blood of five rabbits were pooled and divided into two sub-pools. One was untreated (SEDs), while the other was virally-inactivated with 1% Tri-n-butyl phosphate/1% Triton X-45 at 31°C for 1 h (S/D-SEDs). DES was induced in rabbits using 0.1% benzalkonium chloride (BAC). Rabbits were divided into five groups of two rabbits each. One group was untreated (control), three were treated twice daily for 3 weeks using PBS, SEDs, or S/D-SEDs, and the last received an additional 0.1% BAC (as the negative control). The DES condition was determined by measuring aqueous tear secretion (Schirmer’s test), corneal fluorescein staining, a corneal histologic examination, TUNEL stain apoptosis, and corneal inflammatory marker (tumor necrosis factor-α, interleukin (IL)-1β, IL-8, and IL-6) expressions. We first confirmed that SEDs and S/D-SEDs had similar protein profiles and transforming growth factor (TGF)-β contents. Animal experiments showed that tear secretion did not significantly differ between the SED and S/D-SED groups but was significantly higher than in the PBS group. Eye fluorescein staining revealed dramatic improvements in epithelial defects in groups treated with SEDs or S/D-SEDs, and hematoxylin/eosin staining revealed microscopic epithelial layers similar to those of the untreated controls. Inflammatory markers and TUNEL studies showed that healthy epithelium had been restored in groups treated with SEDs or S/D-SEDs. In conclusion, this preclinical study supports the possibility of using S/D virally inactivated SEDs to treat DES and restore a normal epithelium.
has issue date	2016-04-21(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0153573
bibo:pmid	27100624
has license	cc-by
sha1sum (hex)	46ebfbb3db79bab7f78361721e37e8b35a34037e
schema:url	https://doi.org/10.1371/journal.pone.0153573
resource representing a document's title	Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome
has PubMed Central identifier	PMC4839776
has PubMed identifier	27100624
schema:publication	PLoS One
resource representing a document's body	covid:46ebfbb3db79bab7f78361721e37e8b35a34037e#body_text
is schema:about of	named entity 'RABBIT MODEL' named entity 'revealed' named entity 'staining' named entity 'groups' named entity 'Serum' named entity 'IL-6' named entity 'REVEALED' named entity 'BUT' named entity 'UNTREATED' named entity '3 WEEKS' named entity 'AQUEOUS' named entity 'CONCLUSION' named entity 'SAFETY' named entity 'TRANSFORMING GROWTH FACTOR' named entity 'EYE DROPS' named entity 'SOLVENT' named entity 'HEALTHY' named entity 'RABBITS' named entity 'DRY' named entity 'IL-8' named entity 'DIFFERENT' named entity 'TEST' named entity 'MEASURING' named entity 'CONTENTS' named entity 'NORMAL' named entity 'EXPRESSIONS' named entity 'PRODUCING' named entity 'EVALUATED' named entity 'INTERLEUKIN ' named entity 'HISTOLOGIC EXAMINATION' named entity 'TUNEL' named entity 'INFLAMMATORY MARKERS' named entity 'STUDIES' named entity 'DATA' named entity 'HEMATOXYLIN' named entity 'IMPACTS' named entity 'DRY' named entity 'OCULAR' named entity 'INACTIVATED' named entity 'FLUORESCEIN STAINING' named entity 'SERA' named entity 'EYE' named entity 'TREATED' named entity 'TRI-N-BUTYL PHOSPHATE' named entity 'PREPARED' named entity 'SOLVENT' named entity 'ANIMAL EXPERIMENTS' named entity 'POPULARITY' named entity 'WAY' named entity 'EYE' named entity 'SERUM' named entity 'EPITHELIUM' named entity 'PROTEIN ' named entity 'IS A' named entity 'EYE DROPS' named entity 'INFLAMMATORY MARKER' named entity 'RECEIVED' named entity 'SERUM' named entity 'SEVERE' named entity 'VIRUSES' named entity 'TWICE DAILY' named entity 'RABBIT MODEL' named entity 'INACTIVATED' named entity 'RESOLVE' named entity 'EOSIN' named entity 'TRANSMISSION' named entity 'MEANS' named entity 'HIGHER' named entity 'CONTROL GROUP' named entity 'POOLED' named entity 'TREATED WITH' named entity '1 H' named entity 'APPLICATION' named entity 'ADDITIONAL' named entity 'BLOOD' named entity '2F1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software